U.S Pharmaceutical Market Growth, Size, Trends Analysis - By Molecule, By Product, By Type, By Route of Administration, By Disease, By Age Group, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

U.S Pharmaceutical Market Introduction and Overview

According to SPER market research, 'U.S Pharmaceutical Market Size- By Molecule, By Product, By Type, By Route of Administration, By Disease, By Age Group, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the U.S Pharmaceutical Market is predicted to reach 1138.67 billion by 2034 with a CAGR of 6.01%.

Pharmaceuticals are substances used in the diagnosis, treatment, prevention, and management of diseases and medical conditions. This field encompasses a wide range of products, including prescription drugs, over-the-counter medications, biologics, and vaccines. The pharmaceutical industry plays a critical role in modern healthcare by developing and delivering innovative therapies that improve quality of life and extend life expectancy.

Restraints: Despite being the largest pharmaceutical market in the world, the US faces a number of significant obstacles. The increasing expense of medication development and pricing pressures, which frequently result in political and public scrutiny, is one significant problem. The introduction of innovative treatments may be delayed by complex regulatory procedures and protracted approval procedures. Additionally, branded pharma producers are under pressure to develop quickly due to the increasing competition from generics and biosimilars.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Molecule, By Product, By Type, By Route of Administration, By Disease, By Age Group, By Distribution Channel

Regions covered Northeast, Midwest, West, South

Companies Covered

AbbVie Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, GSK plc, Johnson & Johnson Services, Inc, Merck & Co., Inc, Novartis AG, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited.

U.S Pharmaceutical Market Segmentation:

By Molecule: Based on the Molecule, U.S Pharmaceutical Market is segmented as; Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules).

By Product: Based on the Product, U.S Pharmaceutical Market is segmented as; Branded, Generic.

By Type: Based on the Type, U.S Pharmaceutical Market is segmented as; Prescription, OTC.

By Route of Administration: Based on the Route of Administration, U.S Pharmaceutical Market is Segmented as; Oral, Topical, Parenteral, Inhalation, Others.

By Disease: Based on the Disease, U.S Pharmaceutical Market is Segmented as; Cancer, Diabetes, Obesity, Renal Diseases, Liver Condition, Others.

By Age Group: Based on the Age Group, U.S Pharmaceutical Market is Segmented as; Children & Adolescents, Adults, Geriatric.

By Distribution Channel: Based on the Distribution Channel, U.S Pharmaceutical Market is Segmented as; Hospital Pharmacy, Retail Pharmacy, Others.

By Region: This research also includes data Northeast, Midwest, West, South.

Product Code: PHAR2515

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. U.S Pharmaceutical Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in U.S Pharmaceutical Market

7. U.S Pharmaceutical Market, By Molecule 2021-2034 (USD Million)

7.1. Biologics & Biosimilars (Large Molecules)
- 7.1.1. Monoclonal Antibodies
- 7.1.2. Vaccines
- 7.1.3. Cell & Gene Therapy
- 7.1.4. Others
7.2. Conventional Drugs (Small Molecules)

8. U.S Pharmaceutical Market, By Product 2021-2034 (USD Million)

8.1. Branded
8.2. Generic

9. U.S Pharmaceutical Market, By Type 2021-2034 (USD Million)

9.1. Prescription
9.2. OTC

10. U.S Pharmaceutical Market, By Route of Administration 2021-2034 (USD Million)

10.1. Oral
- 10.1.1. Tablet Capsule
- 10.1.2. Suspensions
- 10.1.3. Other
10.2. Topical
10.3. Parenteral
- 10.3.1. Intravenous
- 10.3.2. Intramuscular
10.4. Inhalations
10.5. Others

11. U.S Pharmaceutical Market, By Disease 2021-2034 (USD Million)

11.1. Cancer
11.2. Diabetes
11.3. Obesity
11.4. Renal Diseases
11.5. Liver Conditions
11.6. Others

12. U.S Pharmaceutical Market, By Age Group 2021-2034 (USD Million)

12.1. Children & Adolescents
12.2. Adults
12.3. Geriatric

13. U.S Pharmaceutical Market, By Distribution Channel 2021-2034 (USD Million)

13.1. Hospital Pharmacy
13.2. Retail Pharmacy
13.3. Others

14. U.S Pharmaceutical Market, 2021-2034 (USD Million)

14.1. U.S Pharmaceutical Market Size and Market Share

15. U.S Pharmaceutical Market, By Region, 2021-2034 (USD Million)

15.1. Northeast
15.2. Midwest
15.3. West
15.4. South

16. Company Profile

16.1. AbbVie Inc
- 16.1.1. Company details
- 16.1.2. Financial outlook
- 16.1.3. Product summary
- 16.1.4. Recent developments
16.2. Bristol-Myers Squibb Company
- 16.2.1. Company details
- 16.2.2. Financial outlook
- 16.2.3. Product summary
- 16.2.4. Recent developments
16.3. F. Hoffmann-La Roche Ltd
- 16.3.1. Company details
- 16.3.2. Financial outlook
- 16.3.3. Product summary
- 16.3.4. Recent developments
16.4. GSK plc
- 16.4.1. Company details
- 16.4.2. Financial outlook
- 16.4.3. Product summary
- 16.4.4. Recent developments
16.5. Johnson & Johnson Services, Inc
- 16.5.1. Company details
- 16.5.2. Financial outlook
- 16.5.3. Product summary
- 16.5.4. Recent developments
16.6. Merck & Co., Inc
- 16.6.1. Company details
- 16.6.2. Financial outlook
- 16.6.3. Product summary
- 16.6.4. Recent developments
16.7. Novartis AG
- 16.7.1. Company details
- 16.7.2. Financial outlook
- 16.7.3. Product summary
- 16.7.4. Recent developments
16.8. Pfizer Inc
- 16.8.1. Company details
- 16.8.2. Financial outlook
- 16.8.3. Product summary
- 16.8.4. Recent developments
16.9. Sanofi
- 16.9.1. Company details
- 16.9.2. Financial outlook
- 16.9.3. Product summary
- 16.9.4. Recent developments
16.10. Takeda Pharmaceutical Company Limited
- 16.10.1. Company details
- 16.10.2. Financial outlook
- 16.10.3. Product summary
- 16.10.4. Recent developments
16.11. Others